Dianthus Therapeutics Inc. Common Stock (DNTH)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earning power and a margin of safety. Dianthus is a clinical-stage biotech with no commercial product; its value depends on claseprubart and DNTH212. The filed numbers show a company consuming capital. In fiscal Q2 2026, the quarter ended 2026-06-30, it reported a net loss of $50.2 million and diluted EPS of -$0.90; in fiscal Q1 2026, the quarter ended 2026-03-31, the net loss was $40.8 million and EPS was -$0.85. For FY2025, the year ended 2025-12-31, revenue was $2.0 million and net loss was $162.3 million, compared with FY2024 revenue of $6.2 million and net loss of $85.0 million. Losses are widening while sales are minimal. FairStock reports no debt, D/E of 0.00, and an Altman Z-Score of 63.32, so near-term solvency does not look like the immediate problem. But trailing free cash flow is -$155.7 million and FCF yield is -3.6%, so outside financing remains likely. At the 2026-10-13 close of $77.58, FairStock calculates P/E of -18.30, P/B of 3.63, ROE of -26.06%, a Piotroski F-Score of 3/9, and a FairStock score of 23/100. The market cap of $4.3 billion against $2.0 million of FY2025 revenue means the price already assumes major pipeline success. Biotech patents and clinical data can offer temporary protection, but without a commercial product there is no Graham-style moat. The Lynch category is none because of losses in each of the last four years. I would treat trial outcomes, cash burn, and dilution as the central variables.

In plain English: Dianthus Therapeutics is a small medical research company that is testing new drugs for serious autoimmune diseases. It is not profitable yet and has very little revenue, so the business currently looks financially weak and depends on outside funding. At $77.58 a share, the price looks expensive compared with today's sales and losses, because investors are paying for future trial success rather than current earnings.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer